Target Ovarian Cancer is closely monitoring the developments relating to the COVID-19 pandemic and the guidance from government bodies. We're committed to minimising the impact on our research programme during this period of uncertainty. We want to enable the researchers that we fund to be safe and support their families, and for clinicians to support the NHS where required.
We've taken the decision to cancel the 2020 grant round for translational research awards. We will be reviewing our plans early in 2021 when we will provide further information about plans to hold the next the grant round.
The guidance on what we're looking for and how to apply is included here for information only.
What we're looking for
We're looking for projects that will optimise and develop more effective and less toxic treatments for ovarian cancer, with a special focus on treatments that will improve overall survival. These awards are not designed for basic or early discovery studies.
Many important challenges need to be overcome to improve treatments for patients. Some examples are provided below. However, we will consider support for any research of relevance to optimising or developing new treatments.
- Identify new drug targets within subtypes of ovarian cancer and develop new targeted treatments
- Understand why tumours develop resistance to therapies, developing strategies to prevent and overcome resistance
- Develop new immunologic approaches to treating ovarian cancer
- Understand the effectiveness of existing drugs against different tumour subtypes
- Understand the effectiveness of specific drug combinations in subtypes
- Research to predict which patients will benefit from chemotherapy
- Develop appropriate treatments for older patients
- Identify prognostic markers that indicate response to treatment
- Develop robust surgical trials to validate new technologies and optimise treatments
For further information about our priorities, read our research strategy [PDF].
- The principal investigator must be from a UK University, Hospital, Clinical Trials Unit or a Research Institute affiliated to one of these organisations.
- The principal investigator must be resident in the UK, and the project and employment must also take place in the UK.
- The award cannot be used to fund principal or co-investigator salaries.
- The award cannot be used to fund a PhD student.
- This award can be used for projects with or without associated salary costs.
- This award can be used for joint funding larger projects providing our standard conditions of grant are not breached.
- Applications will be judged on scientific merit and compliance with our published research strategy.
What we offer
- The maximum period of support is 36 months.
- The maximum value of this grant is £200,000.
- Payment will be quarterly, in arrears.
- No variation (virement) between budget headings is allowed without Target Ovarian Cancer's approval.
- This award is not intended for major equipment and no equipment over £5,000 will be funded.
- We require the project to start within three months of the proposed start date. Please be realistic with your start date (allow time for ethics, recruitment etc).
- 10 per cent of the grant value will be withheld until both end of grant research and finance reports are received by Target Ovarian Cancer.
- We require research updates every six months, detailing progress against research milestones outlined in the original application.
- On average, our grant funding success rate is 18 per cent of all full applications received and 8 per cent of all preliminary applications received.
How to apply
Applications are considered once a year.
Before you fill in the project proposal form, please complete our application checklist: